These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2848 related articles for article (PubMed ID: 19644872)

  • 1. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies.
    Tamai M; Kawakami A; Uetani M; Takao S; Arima K; Iwamoto N; Fujikawa K; Aramaki T; Kawashiri SY; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
    Arthritis Rheum; 2009 Jun; 61(6):772-8. PubMed ID: 19479686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early prediction of joint destruction in rheumatoid arthritis].
    Eguchi K
    Clin Calcium; 2007 Apr; 17(4):517-25. PubMed ID: 17404480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.
    Zeng X; Ai M; Tian X; Gan X; Shi Y; Song Q; Tang F
    J Rheumatol; 2003 Jul; 30(7):1451-5. PubMed ID: 12858440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 143.